Roche Reports Rituxan Survival Data For CLL But Has Captured U.S. Market Before Approval

Adding Rituxan (rituximab) to standard chemotherapy for previously untreated chronic lymphocytic leukemia patients gives them an unprecedented overall survival advantage, but the headline data, presented at the American Society of Hematology meeting in New Orleans Dec. 7, likely won't do much to grow Roche's U.S. bottom line